



National Securities Market Commission  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Colmenar Viejo (Madrid), April 26, 2019

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 226 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following **REGULATORY ANNOUNCEMENT**:

“Pharma Mar, S.A. announces that today a license agreement with Hong Kong listed Luye Pharma Group Ltd. has been executed to develop and commercialize the marine-inspired anti-tumor compound, lurbinectedin (Zepsyre®) in Small Cell Lung Cancer (SCLC), and potentially in other indications in China, Hong Kong and Macao. Luye Pharma will commit to develop lurbinectedin in SCLC in China, while PharmaMar will retain exclusive production rights for the compound.

Under the terms of this agreement, PharmaMar will receive an up-front payment of US \$5 million; also additional payments are contemplated for achievement of regulatory and sales milestones, as well as royalties on sales.

Please find attached press release that will be distribute to the media”.

**Pharma Mar S.A.**  
**Avda. de los Reyes, 1**  
**P.I. La Mina**  
**28770 Colmenar Viejo**  
**(Madrid) Spain**  
**[www.pharmamar.com](http://www.pharmamar.com)**

## **PharmaMar and Luye Pharma sign License agreement for Development and Commercialization of lurbinectedin in China territories**

- **PharmaMar will receive an up-front payment of US \$5 million. Other payments will follow for regulatory milestones and, in addition, for sales and royalties.**
- **WHO estimates that 800,000 new cases of lung cancer will be diagnosed in China by 2020, and cause nearly 700,000 deaths.**

**Madrid, 26<sup>th</sup> of April, 2019.-** PharmaMar (MSE:PHM) has announced today an agreement with Hong Kong listed Luye Pharma Group Ltd. (HKG:2186) to develop and commercialize the marine-inspired anti-tumor compound, lurbinectedin (Zepsyre®) in Small Cell Lung Cancer (SCLC), and potentially in other indications in China, Hong Kong and Macao.

Under the terms of this agreement, PharmaMar will receive an up-front payment of US \$5 million followed by additional payments for regulatory and sales milestones, as well as double-digit royalties. This income may be increased if other therapeutic indications are approved.

Luye Pharma will commit to develop lurbinectedin in SCLC in China, while PharmaMar will retain exclusive production rights for the compound.

**José María Fernández Sousa-Faro, PhD**, President of PharmaMar, commented, *"PharmaMar is delighted to team-up with Luye Pharma Group Ltd. for China, a leader in the above mentioned space with an outstanding track record in Oncology, that has successfully brought innovative cancer medicines to Chinese patients."*

**Rongbing Yang**, President of Luye Pharma Group Ltd., said about this new licensing deal: *"This agreement with PharmaMar enables us to address the treatment of this type of disease in China, which is much more widespread than in the US and Europe. Oncology is one of the core therapeutic areas for Luye Pharma's long-term development. We will continue to increase investment to further enrich our oncology pipelines and enhance our competitiveness in this field of treatment, through external partnerships with more innovative companies such as PharmaMar and also through our in-house R&D innovation".*



According to data from the World Health Organization (WHO), China has the highest number of cancer cases in the world, due to population ageing, tobacco and pollution. China is also the country with the highest mortality rate in Asia for lung cancer. This type of tumor affects a larger number of people than in the U.S., Europe and Japan combined. The WHO estimates that by 2020, 800,000 new cases of lung cancer will be diagnosed and will cause nearly 700,000 deaths. It is estimated that SCLC represents approximately 18% of all lung cancers in China.

#### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States, PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

#### **About Luye Pharma Group**

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe. Luye Pharma has set up 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. The company offers more than 30 products covering the four largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, with business conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as fast growing emerging markets.

#### **About lurbinectedin**

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

**Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127

Miguel Martínez-Cava – Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464

Phone: +34 918466000



**Investor Relations:**

Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)